KRAS Mutation Effective Biomarker For Vectibix Success, Amgen Reports
Biotech adds to industry KRAS buzz with biomarker analysis from its “408” study of the anti-EGFR comparing effectiveness against wild-type and mutated tumors.
Biotech adds to industry KRAS buzz with biomarker analysis from its “408” study of the anti-EGFR comparing effectiveness against wild-type and mutated tumors.